Mangoceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Mangoceuticals, Inc. (MGRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $152.14 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-20
- Mangoceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $152.14K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2023-12-31 | $152.14K 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |